Hosted by Sino-Inno Research Institute and KPMG China and undertaken by Guangdong Medical Valley, the Second Awards Ceremony of Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award & Innovative Biotechnology Development Summit in Greater Bay Area was successfully held on October 16, 2019 in Nansha, Guangzhou.

For the selection of companies, the technological innovation achievement acts as the main standard and three dimensions of technology, market application and capital are taken into account. According to the different development stages of companies, the selected companies are divided into the leading companies, pioneer companies and emerging companies in the medical industry in the Greater Bay Area.

Shenzhen TargetRx Inc. (hereinafter referred to as TargetRx) was listed as the Emerging Company. An emerging company is an unlisted biotechnology company in the round A or earlier financing stages. Dr. Yihan Wang, Founder and Chairman of TargetRx, was invited to attend the award ceremony and receive the award.

△Dr. Yihan Wang, Founder and Chairman of TargetRx, attended the summit and received the award (seventh from right)

In recent years, China is starting to reap the rewards of the effort of cancer prevention and treatment with cancer diagnosis and treatment methods being continuously improved, and a variety of anti-cancer drugs being included in the scope of medical insurance. However, a large number of patients still cannot access and afford the medication. TargetRx will continue to work hard in the R&D of original small molecule targeted anti-cancer drugs with independent intellectual property rights in the field of new drug development. Combined with its own development, TargetRx will continuously improve its core capabilities to make innovation and its market competitiveness, strive to overcome difficulties in the fight against cancer, and develop innovative drugs that patients can afford and have good curative effects to prolong the lives of cancer patients, thus making greater contributions to the development of the biomedical industry in China, including the Guangdong-Hong Kong-Macao Greater Bay Area.